{"id":539748,"date":"2021-04-21T19:04:01","date_gmt":"2021-04-21T19:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=539748"},"modified":"2021-04-21T19:04:01","modified_gmt":"2021-04-21T19:04:01","slug":"oral-mucositis-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-swedish-orphan-biovitrum-ab-oragenics-link-health-pharma-spherium-biomed-galera-therapeutics-and-other","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/oral-mucositis-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-swedish-orphan-biovitrum-ab-oragenics-link-health-pharma-spherium-biomed-galera-therapeutics-and-other_539748.html","title":{"rendered":"Oral Mucositis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Swedish Orphan Biovitrum AB, Oragenics, Link Health Pharma, Spherium Biomed, Galera Therapeutics and Other"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1618994559.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Oral Mucositis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Swedish Orphan Biovitrum AB, Oragenics, Link Health Pharma, Spherium Biomed, Galera Therapeutics and Other\" src=\"https:\/\/www.abnewswire.com\/uploads\/1618994559.jpeg\" alt=\"Oral Mucositis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Swedish Orphan Biovitrum AB, Oragenics, Link Health Pharma, Spherium Biomed, Galera Therapeutics and Other\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Oral Mucositis Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Oral mucositis<\/strong> refers to erythematous, erosive, and ulcerative lesions of the oral mucosa seen in two patient populations: a) Head and Neck cancer patients undergoing radiation therapy to fields involving the oral cavity, b) Patients receiving high-dose chemotherapy for cancer.<\/p>\n<p style=\"text-align: justify;\">Oral mucositis is a significant and dose-limiting toxicity of cancer therapy, with important clinical and economic implications. This article reviews the current knowledge on the pathogenesis, clinical presentation, diagnosis, and management of oral mucositis.<\/p>\n<p style=\"text-align: justify;\"><strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/oral-mucositis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Oral Mucositis Pipeline<\/a> Insight, 2020<\/strong>&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;<strong>Oral Mucositis&nbsp;<\/strong>market. A detailed picture of the&nbsp;<strong>Oral Mucositis&nbsp;<\/strong>pipeline landscape is provided, which includes the disease overview and&nbsp;<strong>Oral Mucositis&nbsp;<\/strong>treatment guidelines.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/oral-mucositis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/oral-mucositis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the Oral Mucositis Companies are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Swedish Orphan Biovitrum AB<\/li>\n<li>Oragenics<\/li>\n<li>Link Health Pharma<\/li>\n<li>Spherium Biomed<\/li>\n<li>Galera Therapeutics<\/li>\n<li>And Many Others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/oral-mucositis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/oral-mucositis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Oral Mucositis Report covers around 3+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late-stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II and Phase I\/II)<\/li>\n<li>Early-stage products (Phase I\/II and Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The launch of the emerging therapies is expected to significantly impact the <strong>Oral Mucositis<\/strong> <strong>treatment<\/strong> scenario in the upcoming years:-<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/oral-mucositis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Oral Mucositis&nbsp;Drugs<\/a><\/strong><strong> Covered:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Kepivance<\/li>\n<li>AG013<\/li>\n<li>Mucomel<\/li>\n<li>GC4419<\/li>\n<li>And Many Others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/oral-mucositis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/oral-mucositis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Oral Mucositis&nbsp;Key Questions<\/strong><strong>:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>What are the current options for&nbsp;<strong>Oral Mucositis&nbsp;treatment<\/strong>?<\/li>\n<li>How many companies are developing therapies for the treatment of&nbsp;<strong>Oral Mucositis<\/strong>?&nbsp;<\/li>\n<li>What are the principal therapies developed by these companies in the industry?<\/li>\n<li>How many therapies are developed by each company for the treatment of&nbsp;<strong>Oral Mucositis<\/strong>?<\/li>\n<li>How many&nbsp;<strong>Oral Mucositis&nbsp;<\/strong>emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of&nbsp;<strong>Oral Mucositis<\/strong>?<\/li>\n<li>Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?&nbsp;<\/li>\n<li>What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact&nbsp;<strong>Oral Mucositis&nbsp;market<\/strong>?&nbsp;<\/li>\n<li>Which are the dormant and discontinued products and the reasons for the same?<\/li>\n<li>What is the unmet need for current therapies for the treatment of&nbsp;<strong>Oral Mucositis<\/strong>?&nbsp;&nbsp;<\/li>\n<li>What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing&nbsp;<strong>Oral Mucositis<\/strong>&nbsp;therapies?&nbsp;<\/li>\n<li>What are the clinical studies going on for&nbsp;<strong>Oral Mucositis&nbsp;<\/strong>and their status?<\/li>\n<li>What are the results of the clinical studies and their safety and efficacy?&nbsp;<\/li>\n<li>What are the key designations that have been granted for the emerging therapies for&nbsp;<strong>Oral Mucositis<\/strong>?&nbsp;<\/li>\n<li>How many patents are granted and pending for the emerging therapies for the treatment of&nbsp;<strong>Oral Mucositis<\/strong>?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: https:\/\/www.delveinsight.com\/sample-request\/oral-mucositis-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Oral Mucositis<\/p>\n<p style=\"text-align: justify;\">3. Oral Mucositis Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">4. Oral Mucositis &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">6. Oral Mucositis Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7. Oral Mucositis Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\">12. Oral Mucositis Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13. Oral Mucositis Product Profiles<\/p>\n<p style=\"text-align: justify;\">Detailed information in the report?<\/p>\n<p style=\"text-align: justify;\">14. Oral Mucositis Key Companies<\/p>\n<p style=\"text-align: justify;\">15. Oral Mucositis Key Products<\/p>\n<p style=\"text-align: justify;\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">17. Oral Mucositis Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Oral Mucositis Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. Oral Mucositis Analyst Review&nbsp;<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC: https:\/\/www.delveinsight.com\/sample-request\/oral-mucositis-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports: <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Oral Mucositis Market<\/strong><\/p>\n<p style=\"text-align: justify;\">The Oral Mucositis (OM) market report provides current treatment practices, emerging drugs, Oral Mucositis (OM) market share of the individual therapies, current and forecasted Oral Mucositis (OM) market Size from 2017 to 2030 segmented by seven major markets.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Oral Mucositis Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The Oral Mucositis epidemiology covered in the report provides historical as well as forecasted Oral Mucositis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><br \/> DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=oral-mucositis-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-swedish-orphan-biovitrum-ab-oragenics-link-health-pharma-spherium-biomed-galera-therapeutics-and-other\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/oral-mucositis-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/oral-mucositis-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/oral-mucositis-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=oral-mucositis-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-swedish-orphan-biovitrum-ab-oragenics-link-health-pharma-spherium-biomed-galera-therapeutics-and-other\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Oral Mucositis Pipeline Oral mucositis refers to erythematous, erosive, and ulcerative lesions of the oral mucosa seen in two patient populations: a) Head and Neck cancer patients undergoing radiation therapy to fields involving the oral cavity, b) Patients receiving high-dose &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/oral-mucositis-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-swedish-orphan-biovitrum-ab-oragenics-link-health-pharma-spherium-biomed-galera-therapeutics-and-other_539748.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-539748","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/539748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=539748"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/539748\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=539748"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=539748"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=539748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}